Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

125.01 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Things About Sarepta Therapeutics Every Smart Investor Knows
Mastering this stock requires appreciating a few scientific nuances. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Can this struggling stock turn its fortunes around? 
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
From Sarepta Therapeutics, Inc.
Via Business Wire
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
Many investors are bailing out, but that might be a mistake. 
Via The Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
These strong stocks are still available at a great price. That may not be the case a whole lot longer. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
1 Gene Therapy Stock to Buy and Hold for the Long Haul
The biotech has what it takes to overcome recent obstacles. 
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
3 Monster Stocks in the Making
These stocks could grow much larger over the next few years. 
Via The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years. 
Via InvestorPlace
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the  
Via Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
Analysts still expect some sizable returns from the stock. 
Via The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
Just because a stock is "on sale" doesn't inherently make it worth purchasing. 
Via The Motley Fool
SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Sarepta Therapeutics to Present at the UBS Biopharma Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.